Literature DB >> 8635193

Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor beta by treatment with bleomycin.

L Yuan1, Y Kuramitsu, Y Li, M Kobayashi, M Hosokawa.   

Abstract

We studied mechanisms of immunosuppression caused by tumor-derived transforming growth factor-beta (TGF beta) and restoration of the immune response by treatment with bleomycin in rats bearing KDH-8 hepatoma. Interleukin-2 (IL-2) production from splenocytes of KDH-8-tumor-bearing rats progressively decreased as the KDH-8 tumor grew. IL-2 production from concanavalin-A-stimulated normal rat splenocytes was significantly inhibited by in vitro cultured KDH-8-tumor-cell-conditioned medium; this inhibition could be blocked by neutralizing the conditioned medium with anti-TGF beta antibody. TGF beta activities were found in KDH-8-tumor-tissue-conditioned medium without acid treatment and were found in tumor-cell-conditioned medium after acid treatment; TGF beta mRNA and TGF beta protein were found in cultured KDH-8 tumor cells. These results suggested that the KDH-8-tumor-derived TGF beta might be involved in the inhibition of IL-2 production from splenocytes. To determine whether bleomycin chemotherapy could reduce tumor-derived TGF beta and restore the immune responses, we treated KDH-8 tumor-bearing rats with bleomycin (5 mg/kg, one shot) at an appropriate time (before the occurrence of immunosuppression) resulting in a significant reduction of TGF beta activity in KDH-8 tumor tissues and restoration of IL-2 production from splenocytes of tumor-bearing rats; KDH-8 tumor growth ultimately regressed. In vitro experiments also showed that TGF beta activity, mRNA expression, and protein synthesis in KDH-8 tumor cells were reduced by bleomycin treatment, and that bleomycin-treated-KDH-8-tumor-cell-conditioned medium did not inhibit IL-2 production from normal rat splenocytes. These results suggest that bleomycin treatment restored IL-2 production in tumor-bearing rats through reducing the tumor-derived TGF beta.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8635193     DOI: 10.1007/bf01526555

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

1.  Immunoregulatory cytokine release in rat spleen cell cultures after treatment with bleomycin and its analogues in vivo.

Authors:  M Micallef; M Hosokawa; T Shibata; A Nakane; Z B Yang; T Minagawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Identification and activation of latent transforming growth factor beta.

Authors:  D A Lawrence
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide.

Authors:  D S Hoon; L J Foshag; A S Nizze; R Bohman; D L Morton
Journal:  Cancer Res       Date:  1990-09-01       Impact factor: 12.701

5.  The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.

Authors:  P Jachimczak; U Bogdahn; J Schneider; C Behl; J Meixensberger; R Apfel; R Dörries; K H Schlingensiepen; W Brysch
Journal:  J Neurosurg       Date:  1993-06       Impact factor: 5.115

6.  Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures.

Authors:  M T Bejarano; R de Waal Malefyt; J S Abrams; M Bigler; R Bacchetta; J E de Vries; M G Roncarolo
Journal:  Int Immunol       Date:  1992-12       Impact factor: 4.823

7.  Interleukin-4 production by the malignant cell line HUT78.

Authors:  W Holter; F S Kalthoff; O Majdic; W Knapp
Journal:  Lymphokine Cytokine Res       Date:  1993-02

8.  Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.

Authors:  L Gorelik; A Prokhorova; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

9.  Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.

Authors:  J J Mulé; S L Schwarz; A B Roberts; M B Sporn; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more
  2 in total

1.  Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes.

Authors:  Kwang-Mi Kim; Ho Won Kim; Jae-Ouk Kim; Kyoung-Min Baek; Joong Gon Kim; Chang-Yuil Kang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  High-intensity focused ultrasound induced apoptosis with caspase 3, 8, and 9/6 activation in rat hepatoma.

Authors:  Naoki Hirokawa; Kazumitsu Koito; Futoshi Okada; Nobuki Kudo; Katsuyuki Yamamoto; Katsuhiko Fujimoto; Mutsumi Nishida; Takeshi Ichimura; Masakazu Hori; Taishi Satoh; Masato Hareyama
Journal:  J Med Ultrason (2001)       Date:  2009-09-04       Impact factor: 1.314

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.